Extended Data Fig. 10: Additional in vivo characterizations of antibody efficacy, pharmacokinetics and safety.

a, Experimental design of prophylactic evaluation of the indicated monoclonal antibodies. n = 4 independent mice for all groups. b, Virus PFU titres in the lung samples of mice prophylactically treated with the indicated monoclonal antibodies. c, Virus RNA (N gene) titres in the lung samples of mice prophylactically treated with IgM-14. The cut-off for the qRT–PCR method, shown as dotted line, is defined as mean + 2 standard deviations of corresponding RNA copies in the qRT–PCR using lung samples from five uninfected mice. d, Viral loads (PFU titres) in the lung samples of mice therapeutically treated with IgM-14 or IgG-14 at the indicated doses. The lines of median lung viral loads are shown for each group. n = 10 biologically independent mice for all groups except that n = 5 for IgM-14 group. A two-sided Mann–Whitney test was used in the statistical analysis for b, d. An ordinary one-way ANOVA with Sidak’s multiple comparisons was used in the statistical analysis for c. e, Sequencing analysis of viruses recovered from lung samples of the ten most outlier mice. A representative chromatogram representing the amino acids 483–489 of the RBD is shown to indicate that no mutations of the critical residues E484 and F486 were observed. f, The plasma concentrations of IgM-14 after a single intranasal dose of 5 mg kg⁻¹ in BALB/c mice. Data are mean ± s.d. of three independent mice. The values lower than LLOQ (0.02 μg ml⁻¹) were defined as 0.01. g, Body weight changes of rats after intranasal administrations of 2 mg kg⁻¹ per dose of IgM-14 or the vehicle control. Data are mean ± s.d. of four independent rats. The arrows indicate dosing twice daily for five consecutive days. Statistical differences between IgM-14 and vehicle groups were analysed by a two-sided multiple t-test. ns, P ≥ 0.05.

Source data